These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39302365)

  • 1. Do Tau Deposition and Glucose Metabolism Dissociate in Alzheimer's Disease Trajectory?
    Nowell J; Raza S; Livingston NR; Sivanathan S; Gentleman S; Edison P
    J Alzheimers Dis; 2024; 101(3):987-999. PubMed ID: 39302365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
    Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
    Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
    Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
    Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
    Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images.
    Malotaux V; Colmant L; Quenon L; Huyghe L; Gérard T; Dricot L; Ivanoiu A; Lhommel R; Hanseeuw B
    J Alzheimers Dis; 2024; 97(1):421-433. PubMed ID: 38108350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
    Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
    Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
    Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
    Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-β but not tau accumulation is strongly associated with longitudinal cognitive decline.
    Wang W; Huang J; Qian S; Zheng Y; Yu X; Jiang T; Ai R; Hou J; Ma E; Cai J; He H; Wang X; Xie C
    CNS Neurosci Ther; 2024 Jul; 30(7):e14860. PubMed ID: 39014268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer's disease.
    Sun X; Nie B; Zhao S; Ai L; Chen Q; Zhang T; Pan T; Wang L; Yin X; Zhang W; Shan B; Liu H; Liang S; Wang G
    Neurosci Lett; 2020 Jan; 717():134699. PubMed ID: 31874218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatially Distributed Amyloid-β Reduces Glucose Metabolism in Mild Cognitive Impairment.
    Carbonell F; Zijdenbos AP; Bedell BJ;
    J Alzheimers Dis; 2020; 73(2):543-557. PubMed ID: 31796668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.